Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

ECHO-COPD: Impact of a Pharmacist-Led Health Belief Model-Based Educational Intervention Among Chronic Obstructive Pulmonary Disease Patients

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease associated with substantial morbidity and mortality, impaired quality of life, and healthcare costs. Medication adherence and appropriate self-management are important components of COPD management; however, patients' health beliefs and perceptions may influence their adherence to treatment and engagement in recommended health behaviours. This study aims to evaluate the impact of a pharmacist-led educational intervention based on the Health Belief Model (HBM) on medication adherence, quality of life, and direct healthcare costs among patients with COPD receiving care at Buraidah Central Hospital (BCH) in Al-Qassim Region, Saudi Arabia. This study will use a quantitative, quasi-experimental pretest-posttest control-group design. Eligible COPD patients will be non-randomly assigned to either an intervention group or a control group. The intervention group will receive structured, pharmacist-led HBM-based educational sessions in addition to routine care. In contrast, the control group will receive standard care without additional education. Baseline assessments will include medication adherence using the Morisky Medication Adherence Scale-8 (MMAS-8); quality of life and health status using the COPD Assessment Test (CAT); health beliefs using a structured HBM questionnaire; and direct medical costs obtained from the hospital clinical cost centre. The educational intervention will be delivered over six months, followed by post-intervention assessment using the same outcome measures.

Participants needed: 140
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: Rabia HussainUpdated: Sep 25, 2026Locations: 1
Eligibility criteria

Be adults aged 18-65 years. [+4]

Are diagnosed with COPD stage IV. [+4]

Status: Not yet recruiting

Impact of PharmaTE Trial on Glycemic Control, Diabetes Knowledge, Medication Adherence and Quality of Life in Type 2 Diabetes Patients: A Mixed-Method Study Protocol

The goal of this clinical trial is to find out whether a pharmacist-led tele-educational program (PharmaTE trial) can help people with type 2 diabetes manage their condition better. The main questions this study aims to answer are: 1. Does the PharmaTE trial improve blood sugar control (HbA1c levels)? 2. Does it help patients better understand their condition? 3. Does it increase how well patients follow their medication schedule? 4. Does it improve the quality of life for patients with type 2 diabetes? 5. Is this type of tele-education program feasible and acceptable for patients? Participants will: Be randomly placed into one of two groups: Intervention group: Receive five virtual education sessions with a clinical pharmacist over the phone or via Zoom (each lasting 20-30 minutes), in addition to their usual diabetes care. Control group: Continue receiving standard diabetes care from their healthcare team without the additional pharmacist-led sessions. Complete assessments at the beginning and end of the study. These include: A blood test for HbA1c , Questionnaires on diabetes knowledge, medication adherence, and quality of life Some participants in the intervention group will be invited for interviews after the sessions to share their experiences and opinions about the program. Who can join? Adults aged 18-65 with uncontrolled type 2 diabetes (HbA1c \> 7%), receiving care at Ibrahim Bin Hamad Obaidullah Hospital in Ras Al-Khaimah, who speak Arabic and can provide consent.

Participants needed: 154
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: Rabia HussainUpdated: Apr 29, 2026
Eligibility criteria

Patients diagnosed with uncontrolled type 2 diabetes (defined as glycated haemog... [+6]

Under 18 years old [+7]